{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T18:36:32Z","timestamp":1770748592725,"version":"3.50.0"},"reference-count":151,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017317","name":"Catholic Medical Center","doi-asserted-by":"publisher","award":["GPP 2022"],"award-info":[{"award-number":["GPP 2022"]}],"id":[{"id":"10.13039\/100017317","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004896","name":"Eisai Incorporated","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004896","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","seizure-journal.com","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure: European Journal of Epilepsy"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.seizure.2023.05.018","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T16:40:21Z","timestamp":1685032821000},"page":"42-57","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion"],"prefix":"10.1016","volume":"110","author":[{"given":"Raman","family":"Sankar","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Chez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1207-8356","authenticated-orcid":false,"given":"J. Eric","family":"Pina-Garza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7801-1741","authenticated-orcid":false,"given":"Tracy","family":"Dixon-Salazar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. Robert","family":"Flamini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2971-7131","authenticated-orcid":false,"given":"Ann","family":"Hyslop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"McGoldrick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John J.","family":"Millichap","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trevor","family":"Resnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jong M.","family":"Rho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7602-3474","authenticated-orcid":false,"given":"Steven","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0001","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1528-1167.1966.tb06263.x","article-title":"Childhood epileptic encephalopathy with diffuse slow spike-waves (otherwise known as \"petit mal variant\") or Lennox syndrome","volume":"7","author":"Gastaut","year":"1966","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0002","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/S1474-4422(08)70292-8","article-title":"Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology","volume":"8","author":"Arzimanoglou","year":"2009","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0003","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1111\/epi.17241","article-title":"International league against epilepsy classification and definition of epilepsy syndromes with onset in childhood: position paper by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Specchio","year":"2022","journal-title":"Epilepsia"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2023.05.018_bib0004","first-page":"S15","article-title":"Evolution and management of Lennox-Gastaut syndrome through adolescence and into adulthood: are seizures always the primary issue?","volume":"13","author":"Kerr","year":"2011","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0005","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1542\/peds.65.1.81","article-title":"West syndrome and Lennox-Gastaut syndrome: a survey of natural history","volume":"65","author":"Kurokawa","year":"1980","journal-title":"Pediatrics"},{"issue":"7466","key":"10.1016\/j.seizure.2023.05.018_bib0006","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature12439","article-title":"Epi4K Consortium and Epilepsy Phenome\/Genome Project. De novo mutations in epileptic encephalopathies","volume":"501","year":"2013","journal-title":"Nature"},{"issue":"Suppl5","key":"10.1016\/j.seizure.2023.05.018_bib0007","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1167.2011.03177.x","article-title":"Definition and natural history of Lennox-Gastaut syndrome","volume":"52","author":"Camfield","year":"2011","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0008","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.seizure.2006.02.012","article-title":"Cognitive effects of seizures","volume":"15","author":"Vingerhoets","year":"2006","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0009","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.seizure.2006.02.019","article-title":"Cognitive problems related to epilepsy syndromes, especially malignant epilepsies","volume":"15","author":"van Rijckevorsel","year":"2006","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.05.018_bib0010","doi-asserted-by":"crossref","first-page":"43276","DOI":"10.1038\/srep43276","article-title":"Abnormal capillary vasodynamics contribute to ictal neurodegeneration in epilepsy","volume":"7","author":"Leal-Campanario","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.seizure.2023.05.018_bib0011","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ebcr.2016.01.004","article-title":"Challenges in identifying Lennox-Gastaut syndrome in adults: a case series illustrating its changing nature","volume":"5","author":"Pina-Garza","year":"2016","journal-title":"Epilepsy Behav Case Rep"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0012","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1528-1157.1998.tb01268.x","article-title":"Antiepileptic drugs as a cause of worsening seizures","volume":"39","author":"Perucca","year":"1998","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0013","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1097\/WNF.0b013e318255b649","article-title":"Lacosamide in Lennox-Gastaut syndrome: case report","volume":"35","author":"Andrade-Machado","year":"2012","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0014","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.yebeh.2010.09.024","article-title":"Does lacosamide aggravate Lennox-Gastaut syndrome? Report on three consecutive cases","volume":"19","author":"Cuzzola","year":"2010","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0015","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S0387-7604(99)00048-0","article-title":"Myoclonic status epilepticus following high-dosage lamotrigine therapy","volume":"21","author":"Guerrini","year":"1999","journal-title":"Brain Dev"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0016","first-page":"852","article-title":"Exacerbation of seizures in Lennox-Gastaut syndrome by gabapentin","volume":"46","author":"Vossler","year":"1996","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0017","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/0887-8994(86)90074-3","article-title":"Carbamazepine-exacerbated epilepsy in children and adolescents","volume":"2","author":"Horn","year":"1986","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.seizure.2023.05.018_bib0018","doi-asserted-by":"crossref","first-page":"505","DOI":"10.3389\/fneur.2017.00505","article-title":"Expert opinion on the management of Lennox-Gastaut syndrome: treatment algorithms and practical considerations","volume":"8","author":"Cross","year":"2017","journal-title":"Front Neurol"},{"key":"10.1016\/j.seizure.2023.05.018_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107146","article-title":"Expert opinion: proposed diagnostic and treatment algorithms for Lennox-Gastaut syndrome in adult patients","volume":"110","author":"Montouris","year":"2020","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.05.018_bib0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.yebeh.2018.08.032","article-title":"Burden of illness in patients with possible Lennox-Gastaut syndrome: a retrospective claims-based study","volume":"88","author":"Reaven","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0021","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1684\/epd.2007.0144","article-title":"Treatment of pediatric epilepsy: European expert opinion, 2007","volume":"9","author":"Wheless","year":"2007","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2023.05.018_bib0022","doi-asserted-by":"crossref","DOI":"10.1177\/17562864221108012","article-title":"Treatment strategies for Lennox-Gastaut syndrome: outcomes of multimodal treatment approaches","volume":"15","author":"Na","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"issue":"Suppl 4","key":"10.1016\/j.seizure.2023.05.018_bib0023","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/epi.12567","article-title":"Lennox-Gastaut syndrome: a consensus approach to differential diagnosis","volume":"55","author":"Bourgeois","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0024","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.yebeh.2018.11.016","article-title":"The refractory epilepsy screening tool for Lennox-Gastaut syndrome (REST-LGS)","volume":"90","author":"Pina-Garza","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.seizure.2023.05.018_bib0025","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s40263-018-0557-x","article-title":"Quantitative pharmaco-electroencephalography in antiepileptic drug research","volume":"32","author":"H\u00f6ller","year":"2018","journal-title":"CNS Drugs"},{"issue":"2\u20133","key":"10.1016\/j.seizure.2023.05.018_bib0026","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.eplepsyres.2010.01.012","article-title":"Lennox-Gastaut syndrome in adulthood: clinical and EEG features","volume":"89","author":"Ferlazzo","year":"2010","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2023.05.018_bib0028","unstructured":"Food and Drug Administration (FDA). Klonopin\u00ae Prescribing Information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/017533s062lbl.pdf; 2023 [accessed 8 February 2023]."},{"key":"10.1016\/j.seizure.2023.05.018_bib0029","first-page":"713","article-title":"Anticonvulsant drugs: mechanisms of action","volume":"44","author":"Macdonald","year":"1986","journal-title":"Adv Neurol"},{"issue":"S1","key":"10.1016\/j.seizure.2023.05.018_bib0030","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/j.1528-1157.2000.tb02165.x","article-title":"Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism","volume":"41","author":"White","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0034","unstructured":"Food and Drug Administration (FDA). Felbatol\u00ae Prescribing Information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/020189s027lbl.pdf; 2012 [last updated 27 August 2012; accessed 8 December 2022]."},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0037","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1002\/ana.410350216","article-title":"Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-d-aspartate and gamma-aminobutyric acidA receptors","volume":"35","author":"Rho","year":"1994","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0036","first-page":"878","article-title":"Felbamate block of the N-methyl-D-aspartate receptor","volume":"273","author":"Subramaniam","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.seizure.2023.05.018_bib0041","unstructured":"Food and Drug Administration (FDA). Lamictal\u00ae prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/020241s064,020764s057,022251s028lbl.pdf; 2021 [accessed 8 December 2022]."},{"issue":"12","key":"10.1016\/j.seizure.2023.05.018_bib0042","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1080\/17512433.2016.1254041","article-title":"A pharmacological overview of lamotrigine for the treatment of epilepsy","volume":"9","author":"Yasam","year":"2016","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0043","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1038\/nn891","article-title":"Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites","volume":"5","author":"Poolos","year":"2002","journal-title":"Nat Neurosci"},{"key":"10.1016\/j.seizure.2023.05.018_bib0048","unstructured":"Food and Drug Administration (FDA). Topamax\u00ae Prescribing Information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/020505s064,020844s054lbl.pdf; 2022 [last updated October 2022; accessed 8 December 2022]."},{"issue":"s1","key":"10.1016\/j.seizure.2023.05.018_bib0049","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1528-1157.2000.tb02163.x","article-title":"An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action","volume":"41","author":"Shank","year":"2000","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0050","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1124\/jpet.109.153908","article-title":"Topiramate reduces excitability in the basolateral amygdala by selectively inhibiting GluK1 (GluR5) kainate receptors on interneurons and positively modulating GABAA receptors on principal neurons","volume":"330","author":"Braga","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.seizure.2023.05.018_bib0055","unstructured":"Food and Drug Administration (FDA). Banzel\u00ae prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/021911s017,201367s008lbl.pdf; 2019 [last updated November 2019; accessed 8 December 2022]."},{"key":"10.1016\/j.seizure.2023.05.018_bib0056","unstructured":"European Medicines Agency (EMA). Inovelon - Summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/inovelon-epar-product-information_en.pdf; 2020 [accessed 8 December 2022]."},{"issue":"7","key":"10.1016\/j.seizure.2023.05.018_bib0057","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1111\/j.1528-1167.2008.01552.x","article-title":"The anticonvulsant profile of rufinamide (CGP 33101) in rodent seizure models","volume":"49","author":"White","year":"2008","journal-title":"Epilepsia"},{"issue":"11","key":"10.1016\/j.seizure.2023.05.018_bib0058","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1111\/epi.14563","article-title":"Recurrent epileptiform discharges in the medial entorhinal cortex of kainate-treated rats are differentially sensitive to antiseizure drugs","volume":"59","author":"West","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0059","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nurt.2006.11.006","article-title":"Rufinamide","volume":"4","author":"Arroyo","year":"2007","journal-title":"Neurotherapeutics"},{"issue":"7","key":"10.1016\/j.seizure.2023.05.018_bib0149","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1111\/j.1528-1167.2008.01665.x","article-title":"Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy","volume":"49","author":"Perucca","year":"2008","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0078","unstructured":"Food and Drug Administration (FDA). Onfi\u00ae prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/202067s006,203993s008lbl.pdf; 2021 [last updated February 2021; accessed 8 December 2022]."},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0080","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2165\/11599020-000000000-00000","article-title":"GABAA receptor physiology and its relationship to the mechanism of action of the 1,5-benzodiazepine clobazam","volume":"26","author":"Sankar","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.seizure.2023.05.018_bib0088","unstructured":"Food and Drug Administration (FDA). Epidiolex\u00ae prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/210365s015lbl.pdf; 2022 [last updated February 2022; accessed 8 December 2022]."},{"key":"10.1016\/j.seizure.2023.05.018_bib0089","unstructured":"European Medicines Agency. Epidyolex - Annex I summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/epidyolex-epar-product-information_en.pdf; 2022 [accessed 8 December 2022]."},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0090","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3390\/ph13080174","article-title":"Receptors and channels possibly mediating the effects of phytocannabinoids on seizures and epilepsy","volume":"13","author":"Senn","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.seizure.2023.05.018_bib0151","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.yebeh.2014.08.135","article-title":"Cannabis, cannabidiol, and epilepsy\u2013from receptors to clinical response","volume":"41","author":"Szaflarski","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.05.018_bib0098","unstructured":"Food and Drug Administration (FDA). Fintepla\u00ae prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2023\/212102s006lbl.pdf; 2023 [last updated January 2023; accessed 8 February 2023]."},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0100","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/dmcn.14822","article-title":"Fenfluramine as antiseizure medication for epilepsy","volume":"63","author":"Gogou","year":"2021","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.seizure.2023.05.018_bib0110","unstructured":"Food and Drug Administration. Depakene (valproic acid) prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/018081s071,018082s054lbl.pdf; 2020 [accessed 8 December 2022]."},{"issue":"10","key":"10.1016\/j.seizure.2023.05.018_bib0111","doi-asserted-by":"crossref","first-page":"926","DOI":"10.2174\/1570159X17666181227165722","article-title":"Valproic acid and epilepsy: from molecular mechanisms to clinical evidences","volume":"17","author":"Romoli","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"10.1016\/j.seizure.2023.05.018_bib0114","unstructured":"Food and Drug Administration (FDA). Keppra\u00ae prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2020\/021035s104,021505s044lbl.pdf; 2020 [last updated September 2020; accessed 8 December 2022]."},{"key":"10.1016\/j.seizure.2023.05.018_bib0115","unstructured":"European Medicines Agency. Keppra - Annex 1 summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keppra-epar-product-information_en.pdf; 2022 [accessed 8 December 2022]."},{"issue":"26","key":"10.1016\/j.seizure.2023.05.018_bib0116","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.seizure.2023.05.018_bib0122","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.nbd.2018.03.015","article-title":"A novel action of lacosamide on GABAA currents sets the ground for a synergic interaction with levetiracetam in treatment of epilepsy","volume":"115","author":"Ruffolo","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.seizure.2023.05.018_bib0119","unstructured":"Food and Drug Administration (FDA). Vimpat\u00ae prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/022253s055,022254s045,022255s037lbl.pdf; 2022 [last updated September 2022; accessed 8 December 2022]."},{"key":"10.1016\/j.seizure.2023.05.018_bib0120","unstructured":"European Medicines Agency. Vimpat - Annex 1 summary of product characteristics, https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/vimpat-epar-product-information_en.pdf; 2022 [accessed 8 December 2022]."},{"key":"10.1016\/j.seizure.2023.05.018_bib0027","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.seizure.2022.07.004","article-title":"An Italian consensus on the management of Lennox-Gastaut syndrome","volume":"101","author":"Riva","year":"2022","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.seizure.2023.05.018_bib0031","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/sj.bjp.0706796","article-title":"Mechanism of action of benzodiazepines on GABAA receptors","volume":"148","author":"Campo-Soria","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0032","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1177\/1087057113501555","article-title":"Determining the relative efficacy of positive allosteric modulators of the GABAA receptor: design of a screening approach","volume":"19","author":"Ghisdal","year":"2014","journal-title":"J Biomol Screen"},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0033","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1528-1157.1973.tb03953.x","article-title":"Treatment of infantile spasms and Lennox-Gastaut syndrome with clonazepam (Rivotril)","volume":"14","author":"Vassella","year":"1973","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0035","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002018-199921030-00006","article-title":"Felbamate in epilepsy therapy: evaluating the risks","volume":"21","author":"Pellock","year":"1999","journal-title":"Drug Saf"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0038","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1056\/NEJM199301073280105","article-title":"The Felbamate Study Group in Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox-Gastaut syndrome)","volume":"328","year":"1993","journal-title":"N Engl J Med"},{"issue":"2\u20133","key":"10.1016\/j.seizure.2023.05.018_bib0039","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0920-1211(98)00119-3","article-title":"The efficacy of felbamate as add-on therapy to valproic acid in the Lennox-Gastaut syndrome","volume":"34","author":"Siegel","year":"1999","journal-title":"Epilepsy Res"},{"issue":"Suppl 7","key":"10.1016\/j.seizure.2023.05.018_bib0040","first-page":"S18","article-title":"Felbamate in the treatment of Lennox-Gastaut syndrome: results of a 12-month open-label study following a randomized clinical trial","volume":"34","author":"Dodson","year":"1993","journal-title":"Epilepsia"},{"issue":"25","key":"10.1016\/j.seizure.2023.05.018_bib0044","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJM199712183372504","article-title":"Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome","volume":"337","author":"Motte","year":"1997","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.seizure.2023.05.018_bib0051","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1212\/WNL.52.9.1882","article-title":"A double-blind, randomized trial of topiramate in Lennox-Gastaut syndrome","volume":"52","author":"Sachdeo","year":"1999","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.seizure.2023.05.018_bib0052","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1111\/j.1528-1157.2000.tb02179.x","article-title":"Topiramate in Lennox-Gastaut syndrome: open-label treatment of patients completing a randomized controlled trial","volume":"41","author":"Glauser","year":"2000","journal-title":"Epilepsia"},{"issue":"21","key":"10.1016\/j.seizure.2023.05.018_bib0060","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1212\/01.wnl.0000303813.95800.0d","article-title":"Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome","volume":"70","author":"Glauser","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2023.05.018_bib0061","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1600-0404.2010.01334.x","article-title":"Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study","volume":"122","author":"Kluger","year":"2010","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2023.05.018_bib0064","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.eplepsyres.2014.08.019","article-title":"Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan","volume":"108","author":"Ohtsuka","year":"2014","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.seizure.2023.05.018_bib0065","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2016.01.002","article-title":"Long-term safety and seizure outcome in Japanese patients with Lennox-Gastaut syndrome receiving adjunctive rufinamide therapy: an open-label study following a randomized clinical trial","volume":"121","author":"Ohtsuka","year":"2016","journal-title":"Epilepsy Res"},{"issue":"15","key":"10.1016\/j.seizure.2023.05.018_bib0082","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.1212\/WNL.0b013e318232de76","article-title":"Randomized, phase III study results of clobazam in Lennox-Gastaut syndrome","volume":"77","author":"Ng","year":"2011","journal-title":"Neurology"},{"issue":"20","key":"10.1016\/j.seizure.2023.05.018_bib0091","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1056\/NEJMoa1714631","article-title":"Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome","volume":"378","author":"Devinsky","year":"2018","journal-title":"N Engl J Med"},{"issue":"10125","key":"10.1016\/j.seizure.2023.05.018_bib0092","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S0140-6736(18)30136-3","article-title":"Cannabidiol in patients with seizures associated with Lennox-Gastaut syndrome (GWPCARE4): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"391","author":"Thiele","year":"2018","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0102","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamaneurol.2022.0829","article-title":"Efficacy and safety of fenfluramine for the treatment of seizures associated with Lennox-Gastaut Syndrome: a randomized clinical trial","volume":"79","author":"Knupp","year":"2022","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0103","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/epi.17431","article-title":"Fenfluramine provides clinically meaningful reduction in frequency of drop seizures in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study","volume":"64","author":"Knupp","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0107","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2021.106646","article-title":"A phase 1b\/2a study of soticlestat as adjunctive therapy in participants with developmental and\/or epileptic encephalopathies","volume":"174","author":"Halford","year":"2021","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0045","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1528-1157.1997.tb01079.x","article-title":"Lamotrigine adjunctive therapy in childhood epileptic encephalopathy (the Lennox Gastaut syndrome)","volume":"38","author":"Donaldson","year":"1997","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0046","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1159\/000116849","article-title":"Lamotrigine as an add-on drug in the management of Lennox-Gastaut syndrome","volume":"32","author":"Timmings","year":"1992","journal-title":"Eur Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2023.05.018_bib0047","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1468-1331.1995.tb00164.x","article-title":"Lamotrigine use in twelve patients with the Lennox-Gastaut syndrome","volume":"2","author":"Buchanan","year":"1995","journal-title":"Eur J Neurol"},{"issue":"2a","key":"10.1016\/j.seizure.2023.05.018_bib0053","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1590\/S0004-282X1999000200001","article-title":"A pilot study of topiramate in children with Lennox-Gastaut syndrome","volume":"57","author":"Guerreiro","year":"1999","journal-title":"Arq Neuropsiquiatr"},{"issue":"1\u20132","key":"10.1016\/j.seizure.2023.05.018_bib0054","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S0920-1211(02)00103-1","article-title":"Topiramate as add-on drug in children, adolescents and young adults with Lennox-Gastaut syndrome: an Italian multicentric study","volume":"51","author":"Coppola","year":"2002","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0062","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40120-016-0041-9","article-title":"Treatment of adults with Lennox-Gastaut syndrome: further analysis of efficacy and safety\/Tolerability of rufinamide","volume":"5","author":"McMurray","year":"2016","journal-title":"Neurol Ther"},{"key":"10.1016\/j.seizure.2023.05.018_bib0063","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108275","article-title":"Safety and efficacy of rufinamide in children and adults with Lennox-Gastaut syndrome: a post hoc analysis from Study 022","volume":"124","author":"Arzimanoglou","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"9","key":"10.1016\/j.seizure.2023.05.018_bib0066","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.seizure.2010.09.008","article-title":"Rufinamide in children and adults with Lennox-Gastaut syndrome: first Italian multicenter experience","volume":"19","author":"Coppola","year":"2010","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0067","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.seizure.2012.02.006","article-title":"Rufinamide as an adjuvant treatment in children with Lennox-Gastaut syndrome","volume":"21","author":"Kim","year":"2012","journal-title":"Seizure"},{"issue":"7","key":"10.1016\/j.seizure.2023.05.018_bib0068","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.clineuro.2012.09.021","article-title":"Effectiveness and tolerability of rufinamide in children and young adults with Lennox-Gastaut syndrome: a single center study in Korea","volume":"115","author":"Lee","year":"2013","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.seizure.2023.05.018_bib0069","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.yebeh.2017.08.026","article-title":"Real-world data on rufinamide treatment in patients with Lennox-Gastaut syndrome: results from a European noninterventional registry study","volume":"76","author":"Nikanorova","year":"2017","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0070","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/epi.17601","article-title":"Long-term effectiveness of add-on perampanel in patients with Lennox-Gastaut syndrome: a multicenter retrospective study","volume":"64","author":"Matricardi","year":"2023","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0071","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.yebeh.2008.12.013","article-title":"Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience","volume":"14","author":"Kluger","year":"2009","journal-title":"Epilepsy Behav"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0072","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.pediatrneurol.2010.04.003","article-title":"Experience with rufinamide in a pediatric population: a single center's experience","volume":"43","author":"Vendrame","year":"2010","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0073","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1684\/epd.2013.0557","article-title":"Short-term efficacy and tolerability of rufinamide adjunctive therapy in children with refractory generalised epilepsy","volume":"15","author":"Kim","year":"2013","journal-title":"Epileptic Disord"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0074","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.eplepsyres.2014.01.013","article-title":"Rufinamide for the treatment of refractory epilepsy secondary to neuronal migration disorders","volume":"108","author":"Cusmai","year":"2014","journal-title":"Epilepsy Res"},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0075","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1111\/epi.12689","article-title":"Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience","volume":"55","author":"Thome-Souza","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0076","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eplepsyres.2015.02.003","article-title":"Retention rates of rufinamide in pediatric epilepsy patients with and without Lennox-Gastaut syndrome","volume":"112","author":"Kessler","year":"2015","journal-title":"Epilepsy Res"},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0077","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/epi4.12314","article-title":"Novel seizure outcomes in patients with Lennox-Gastaut syndrome: post hoc analysis of seizure-free days in rufinamide Study 303","volume":"4","author":"Auvin","year":"2019","journal-title":"Epilepsia Open"},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0079","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1111\/j.1528-1157.1996.tb00643.x","article-title":"Effects of clobazam and its active metabolite on GABA-activated currents in rat cerebral neurons in culture","volume":"37","author":"Nakamura","year":"1996","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.seizure.2023.05.018_bib0081","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1111\/j.1528-1167.2008.01935.x","article-title":"Clobazam in the treatment of Lennox-Gastaut syndrome","volume":"50","author":"Conry","year":"2009","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0083","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.yebeh.2012.09.039","article-title":"Long-term safety and efficacy of clobazam for Lennox-Gastaut syndrome: interim results of an open-label extension study","volume":"25","author":"Ng","year":"2012","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0084","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/epi.12561","article-title":"Stable dosages of clobazam for Lennox-Gastaut syndrome are associated with sustained drop-seizure and total-seizure improvements over 3 years","volume":"55","author":"Conry","year":"2014","journal-title":"Epilepsia"},{"issue":"17","key":"10.1016\/j.seizure.2023.05.018_bib0085","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1212\/WNL.0000000000003253","article-title":"Deconstructing tolerance with clobazam: post hoc analyses from an open-label extension study","volume":"87","author":"Gidal","year":"2016","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0086","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/WNF.0b013e3182770730","article-title":"Long-term use of clobazam in Lennox-Gastaut syndrome: experience in a single tertiary epilepsy center","volume":"36","author":"Lee","year":"2013","journal-title":"Clin Neuropharmacol"},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0087","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1177\/0883073819836534","article-title":"Evaluation of the effects of clobazam on seizure control and quality of life in children with Lennox-Gastaut syndrome: a pilot study","volume":"34","author":"Weinstock","year":"2019","journal-title":"J Child Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0093","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/epi.14670","article-title":"Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study","volume":"60","author":"Thiele","year":"2019","journal-title":"Epilepsia"},{"issue":"9","key":"10.1016\/j.seizure.2023.05.018_bib0094","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1111\/epi.17000","article-title":"Long-term safety and efficacy of add-on cannabidiol in patients with Lennox-Gastaut syndrome: results of a long-term open-label extension trial","volume":"62","author":"Patel","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2023.05.018_bib0096","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.673135","article-title":"Results from an Italian expanded access program on cannabidiol treatment in highly refractory Dravet syndrome and Lennox-Gastaut syndrome","volume":"12","author":"Iannone","year":"2021","journal-title":"Front Neurol"},{"issue":"50","key":"10.1016\/j.seizure.2023.05.018_bib0097","doi-asserted-by":"crossref","first-page":"e427","DOI":"10.3346\/jkms.2020.35.e427","article-title":"Cannabidiol for treating Lennox-Gastaut syndrome and Dravet syndrome in Korea","volume":"35","author":"Koo","year":"2020","journal-title":"J Korean Med Sci"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0099","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/epi.14658","article-title":"Fenfluramine, a serotonin-releasing drug, prevents seizure-induced respiratory arrest and is anticonvulsant in the DBA\/1 mouse model of SUDEP","volume":"60","author":"Tupal","year":"2019","journal-title":"Epilepsia"},{"issue":"10","key":"10.1016\/j.seizure.2023.05.018_bib0101","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/epi.14540","article-title":"A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in Lennox-Gastaut syndrome","volume":"59","author":"Lagae","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0104","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.seizure.2019.12.012","article-title":"Open-label, uncontrolled retrospective study of perampanel in adults with Lennox-Gastaut syndrome","volume":"75","author":"Crespel","year":"2020","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2023.05.018_bib0105","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2017.05.036","article-title":"Use of perampanel in children and adolescents with Lennox-Gastaut syndrome","volume":"74","author":"Auvin","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.05.018_bib0106","unstructured":"Ngo, L. Perampanel update on Lennox-Gastaut syndrome. In: EILAT xvi, 22\u201325 May 2022, Madrid, Spain, 2022."},{"issue":"10","key":"10.1016\/j.seizure.2023.05.018_bib0108","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.1111\/epi.17367","article-title":"A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)","volume":"63","author":"Hahn","year":"2022","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.seizure.2023.05.018_bib0109","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1212\/WNL.0000000000006432","article-title":"Lorcaserin therapy for severe epilepsy of childhood onset: a case series","volume":"91","author":"Tolete","year":"2018","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0112","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2165\/00002018-200022060-00005","article-title":"A risk-benefit assessment of therapies for Lennox-Gastaut syndrome","volume":"22","author":"Schmidt","year":"2000","journal-title":"Drug Saf"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0113","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1528-1157.1982.tb05085.x","article-title":"Sodium valproate: monotherapy and polytherapy","volume":"23","author":"Covanis","year":"1982","journal-title":"Epilepsia"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0117","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.pediatrneurol.2014.06.004","article-title":"Adjunctive levetiracetam treatment in pediatric Lennox-Gastaut syndrome","volume":"51","author":"Kim","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2023.05.018_bib0118","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.nrl.2010.10.012","article-title":"Levetiracetam efficacy in patients with Lennox-Gastaut syndrome. Presentation of a case","volume":"26","author":"D\u00edaz Negrillo","year":"2011","journal-title":"Neurologia"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0121","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/epi.13602","article-title":"Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow Na(+) channel inactivation","volume":"58","author":"Holtkamp","year":"2017","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0123","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ane.12221","article-title":"Efficacy and tolerability of add-on lacosamide in children with Lennox-Gastaut syndrome","volume":"129","author":"Grosso","year":"2014","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2023.05.018_bib0124","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.seizure.2015.10.009","article-title":"Efficacy and tolerability of add-on Lacosamide treatment in adults with Lennox-Gastaut syndrome: an observational study","volume":"33","author":"Andrade-Machado","year":"2015","journal-title":"Seizure"},{"issue":"4","key":"10.1016\/j.seizure.2023.05.018_bib0125","article-title":"Anti-seizure medications for Lennox-Gastaut syndrome","volume":"4","author":"Brigo","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.seizure.2023.05.018_bib0126","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/dmcn.15072","article-title":"Efficacy and safety of antiseizure medication for Lennox-Gastaut syndrome: a systematic review and network meta-analysis","volume":"64","author":"Zhang","year":"2022","journal-title":"Dev Med Child Neurol"},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0127","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1111\/j.1528-1157.1999.tb00831.x","article-title":"Adding lamotrigine to valproate: incidence of rash and other adverse effects","volume":"40","author":"Faught","year":"1999","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0128","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FTD.0b013e31820fa9ad","article-title":"Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication","volume":"33","author":"May","year":"2011","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.seizure.2023.05.018_bib0129","unstructured":"Food and Drug Administration (FDA). Depakote\u00ae prescribing information, https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/018723s061lbl.pdf; 2019 [last updated 02\/21\/2019; accessed 8 December 2022]."},{"issue":"7","key":"10.1016\/j.seizure.2023.05.018_bib0130","first-page":"887","article-title":"Absence status and the concurrent administration of clonazepam and valproate sodium","volume":"36","author":"Watson","year":"1979","journal-title":"Am J Hosp Pharm"},{"issue":"1","key":"10.1016\/j.seizure.2023.05.018_bib0131","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1469-8749.1977.tb08015.x","article-title":"Treatment of generalized epilepsies of childhood and adolescence with sodium valproate (\"epilim\")","volume":"19","author":"Jeavons","year":"1977","journal-title":"Dev Med Child Neurol"},{"issue":"Suppl 2","key":"10.1016\/j.seizure.2023.05.018_bib0132","first-page":"S30","article-title":"Vigabatrin in childhood epilepsy","author":"Dulac","year":"1991","journal-title":"J Child Neurol"},{"issue":"11 Suppl 5","key":"10.1016\/j.seizure.2023.05.018_bib0133","first-page":"S24","article-title":"The potential for increasing seizure frequency, relapse, and appearance of new seizure types with vigabatrin","volume":"43","author":"Lortie","year":"1993","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.seizure.2023.05.018_bib0134","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/epi.16355","article-title":"Coadministered cannabidiol and clobazam: preclinical evidence for both pharmacodynamic and pharmacokinetic interactions","volume":"60","author":"Anderson","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2019.106459","article-title":"Drug-drug interactions and pharmacodynamics of concomitant clobazam and cannabidiol or stiripentol in refractory seizures","volume":"99","author":"Klein","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0136","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/bcp.14158","article-title":"Clinical trial simulations of the interaction between cannabidiol and clobazam and effect on drop-seizure frequency","volume":"86","author":"Bergmann","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0137","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A Phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"10","key":"10.1016\/j.seizure.2023.05.018_bib0138","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1002\/jcph.1634","article-title":"A Phase 2, double-blind, placebo-controlled trial to investigate potential drug-drug interactions between cannabidiol and clobazam","volume":"60","author":"VanLandingham","year":"2020","journal-title":"J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.seizure.2023.05.018_bib0139","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41582-022-00651-8","article-title":"The metabolic basis of epilepsy","volume":"18","author":"Rho","year":"2022","journal-title":"Nat Rev Neurol"},{"key":"10.1016\/j.seizure.2023.05.018_bib0140","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/bs.irn.2022.06.002","article-title":"Interactions between the gut microbiome and ketogenic diet in refractory epilepsy","volume":"167","author":"\u00d6zcan","year":"2022","journal-title":"Int Rev Neurobiol"},{"key":"10.1016\/j.seizure.2023.05.018_bib0141","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106454","article-title":"Ketogenic diet and neuroinflammation","volume":"167","author":"Koh","year":"2020","journal-title":"Epilepsy Res"},{"issue":"7","key":"10.1016\/j.seizure.2023.05.018_bib0142","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1111\/j.1528-1157.1998.tb01155.x","article-title":"Locus coeruleus lesions suppress the seizure-attenuating effects of vagus nerve stimulation","volume":"39","author":"Krahl","year":"1998","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0143","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1124\/jpet.106.104166","article-title":"Effect of vagus nerve stimulation on serotonergic and noradrenergic transmission","volume":"318","author":"Dorr","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl 5","key":"10.1016\/j.seizure.2023.05.018_bib0144","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1528-1167.2011.03179.x","article-title":"Strategies for transitioning to adult care for youth with Lennox-Gastaut syndrome and related disorders","volume":"52","author":"Camfield","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2023.05.018_bib0145","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.yebeh.2017.05.021","article-title":"Assessment of treatment patterns and healthcare costs associated with probable Lennox-Gastaut syndrome","volume":"73","author":"Pi\u00f1a-Garza","year":"2017","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2023.05.018_bib0146","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107647","article-title":"Epidemiology, healthcare resource use, and mortality in patients with probable Lennox-Gastaut syndrome: a population-based study on German health insurance data","volume":"115","author":"Strzelczyk","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"8","key":"10.1016\/j.seizure.2023.05.018_bib0147","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1212\/WNL.0000000000200779","article-title":"Changes in the use of brand name and generic medications and total prescription cost among medicare beneficiaries with epilepsy","volume":"99","author":"Terman","year":"2022","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.seizure.2023.05.018_bib0148","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/ane.12086","article-title":"Indirect comparison of clobazam and other therapies for Lennox-Gastaut syndrome","volume":"128","author":"Cramer","year":"2013","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.seizure.2023.05.018_bib0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107445","article-title":"Cognitive, adaptive, and behavioral effects of adjunctive rufinamide in Lennox-Gastaut syndrome: a prospective observational clinical study","volume":"112","author":"Operto","year":"2020","journal-title":"Epilepsy Behav"}],"container-title":["Seizure: European Journal of Epilepsy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123001498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131123001498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,2]],"date-time":"2024-08-02T16:43:21Z","timestamp":1722617001000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131123001498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":151,"alternative-id":["S1059131123001498"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2023.05.018","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Proposed anti-seizure medication combinations with rufinamide in the treatment of Lennox-Gastaut syndrome: Narrative review and expert opinion","name":"articletitle","label":"Article Title"},{"value":"Seizure: European Journal of Epilepsy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2023.05.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}